On-Demand: COVID-19 Test & Treat Townhall
Our COVID-19 Test & Treat Townhall answered ground-breaking questions related to the unique challenges we face as we navigate testing and treating COVID-19 in the pharmacy environment.
The ability for pharmacists to test and prescribe treatment for COVID-19 has been approved at the national level thanks to the PREP Act. And with two COVID-19 antiviral pills getting ready for release soon, we’re hearing a lot of questions about how to operationalize this opportunity.
While many pharmacies are already providing COVID-19 testing, leveraging those test results to evaluate a patient and prescribe treatment when appropriate is uncharted territory.
During a recent townhall, XiFin Pharmacy Solutionss medical billing and clinical services experts David Pope, PharmD, CDE and Shelley Hansell shared key details on COVID-19 test and treat, and answered dozens of questions from pharmacies all around the country about this emerging opportunity.
Topics covered include:
- Documentation requirements
- Reimbursement process and requirements
- Contracting and credentialing
- Steps for pharmacists to act as a prescribers
- State and federal reporting requirements
Some of the burning questions answered by our expert panelists:
- Should pharmacies be reimbursed for the act of evaluating and prescribing or should pharmacists?
- What am I required to document for both the test and the treatment?
- Can you walk me through the steps I need to take to act as a prescriber?